Physician profile
Alison Lee Baker
NPI 1528710274
$5,656.12
in general payments reported to CMS, 2019-2025
26 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $709 · 2023: $1,450 · 2024: $2,155 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,947.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,267.15 | 2022-2025 | |
| Alkermes, INC. | $722.62 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $586.88 | 2022-2025 | Caplyta |
| Tris Pharma INC | $521.01 | 2022-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $395.45 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $310.69 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $309.35 | 2022-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $227.08 | 2022-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $225.20 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $172.39 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $157.05 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $155.63 | 2023-2025 | Auvelity |
| Corium, LLC | $150.62 | 2022-2024 | Azstarys |
| Noven Therapeutics, LLC | $92.79 | 2024 | Xelstrym, Secuado |
| Indivior INC. | $53.85 | 2022-2024 | Perseris |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.89 | 2022-2023 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $42.09 | 2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $37.38 | 2024 | Relexxii |
| Sunovion Pharmaceuticals INC. | $34.76 | 2022 | |
| Almatica Pharma LLC | $30.61 | 2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $28.42 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $26.61 | 2022-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $22.35 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.13 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $12.24 | 2022 | |
| Eisai INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.